When antivirals backfire: An evaluation of favipiravir’s clinical outcomes in critically ill patients with COVID-19: A multicenter cohort study

[1]  Ohoud Aljuhani,et al.  Standard dosing of enoxaparin versus unfractionated heparin in critically ill patient with COVID-19: a multicenter propensity-score matched study , 2022, Thrombosis Journal.

[2]  Ohoud Aljuhani,et al.  Evaluation of inhaled nitric oxide (iNO) treatment for moderate-to-severe ARDS in critically ill patients with COVID-19: a multicenter cohort study , 2022, Critical Care.

[3]  Fan Yang,et al.  A systematic review and Bayesian network meta-analysis for comparative safety assessment of favipiravir interventions in hospitalized COVID-19 patients. , 2022, Journal of Infection in Developing Countries.

[4]  Chih-Cheng Lai,et al.  Favipiravir-based treatment for outcomes of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials , 2022, Expert review of clinical pharmacology.

[5]  S. Al‐Muhsen,et al.  Favipiravir Effectiveness and Safety in Hospitalized Moderate-Severe COVID-19 Patients: Observational Prospective Multicenter Investigation in Saudi Arabia , 2022, Frontiers in Medicine.

[6]  Reed J. D. Sorensen,et al.  Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21 , 2022, The Lancet.

[7]  Ohoud Aljuhani,et al.  Statins and Risk of Thrombosis in Critically ill Patients with COVID-19: A Multicenter Cohort Study , 2022, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[8]  Ohoud Aljuhani,et al.  Association between tocilizumab and emerging multidrug-resistant organisms in critically ill patients with COVID-19: A multicenter, retrospective cohort study , 2021, BMC Infectious Diseases.

[9]  N. Zakiyah,et al.  Effectiveness of Remdesivir, Lopinavir/Ritonavir, and Favipiravir for COVID-19 Treatment: A Systematic Review , 2021, International journal of general medicine.

[10]  M. Gönen,et al.  Effectiveness of favipiravir in COVID-19: a live systematic review , 2021, European Journal of Clinical Microbiology & Infectious Diseases.

[11]  Kei Irie,et al.  Population pharmacokinetics of favipiravir in patients with COVID‐19 , 2021, CPT: pharmacometrics & systems pharmacology.

[12]  W. Jang,et al.  Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay , 2021, Proceedings of the National Academy of Sciences.

[13]  Ohoud Aljuhani,et al.  Evaluation of zinc sulfate as an adjunctive therapy in COVID-19 critically ill patients: a two center propensity-score matched study , 2021, Critical Care.

[14]  Z. Memish,et al.  The Saudi Critical Care Society practice guidelines on the management of COVID-19 in the ICU: Therapy section , 2021, Journal of Infection and Public Health.

[15]  H. Akatsu,et al.  Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis , 2021, BMC Infectious Diseases.

[16]  I. Abraham,et al.  Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysis , 2021, Current medical research and opinion.

[17]  M. Solaymani-Dodaran,et al.  Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia , 2021, International Immunopharmacology.

[18]  M. Arab-Zozani,et al.  The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials , 2021, Scientific Reports.

[19]  Abdulmalik M. Alkatheri,et al.  Clinical features and outcomes of critically ill patients with coronavirus disease 2019 (COVID-19): A multicenter cohort study , 2021, International Journal of Infectious Diseases.

[20]  S. Aydoğan,et al.  Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir , 2020, Journal of Infection and Public Health.

[21]  P. Horby,et al.  Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza , 2020, EBioMedicine.

[22]  M. Munir,et al.  The efficacy and safety of antivirus drugs for COVID-19: A systematic review , 2020 .

[23]  N. Ford,et al.  Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID‐19: initial assessment , 2020, Journal of the International AIDS Society.

[24]  A. Shehata,et al.  The COVID-19 Pandemic: A Comprehensive Review of Taxonomy, Genetics, Epidemiology, Diagnosis, Treatment, and Control , 2020, Journal of clinical medicine.

[25]  Wu Zhong,et al.  Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.

[26]  Y. Furuta,et al.  Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase , 2017, Proceedings of the Japan Academy. Series B, Physical and biological sciences.

[27]  D. Smee,et al.  T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections , 2009, Antiviral Research.

[28]  K. Bhaskaran,et al.  The effectiveness of , 2014 .